25 May 2023: Clinical Research
Impact of Converting from Immediate-Release Tacrolimus to Envarsus on BK Viremia Incidence in Kidney Transplant Patients with Rapid Metabolism
Graham Towns ABCDEFG* , Gaurav Agarwal ABCDEFG , Ashutosh Tamhane CDE , Clifton Kew AEDOI: 10.12659/MSM.939748
Med Sci Monit 2023; 29:e939748
Table 1 Demographic data at baseline and at enrollment at 2 months post-transplant.
| Variables | All (n=88) | Envarsus group (n=43) | IR-Tac group (n=45) | p-value |
|---|---|---|---|---|
| Type of transplant n(%) | 0.162 | |||
| Living donor | 7 (7.6) | 1 (2.3) | 6 (13.3) | |
| Deceased donor | 79 (89.8) | 41 (95.4) | 38 (84.4) | |
| Simultaneous kidney pancreas | 2 (2.3) | 1 (2.3) | 1 (2.2) | |
| Age years at transplant, mean (SD) | 50.2 (10.3) | 49.4 (10.1) | 50.9 (10.5) | 0.491 |
| Race (African American) n (%) | 78 (88.6) | 40 (93.0) | 38 (84.4) | 0.352 |
| Gender (Female) n (%) | 27 (30.7) | 12 (27.9) | 15 (33.3) | 0.749 |
| CPRA, median (Q1–Q3) | 3 (0–32.8) | 0 (0–3.0) | 4 (0–74.0) | 0.019 |
| Creatinine in mg/dL, mean (SD) | 1.7 (0.6) | 1.6 (0.5) | 1.7 (0.6) | 0.892 |
| Urine protein creatinine ratio in g/g, median (Q1–Q3) | 0.2 (0.1–0.3) | 0.1 (0.1–0.3) | 0.2 (0.2–0.5) | 0.028 |
| Tacrolimus dose in mg/day, mean (SD) | 15.7 (4.5) | 17.3 (5.2) | 14.3 (3.2) | 0.002 |
| Tacrolimus level in ng/mL, mean (SD) | 9.7 (3.0) | 10.0 (3.6) | 9.4 (2.3) | 0.310 |
| C/D ratio, mean (SD) | 0.7 (0.2) | 0.6 (0.3) | 0.7 (0.2) | 0.247 |
| MMF dose (mg/day), median (Q1–Q3) | 2000 (2000–2000) | 2000 (2000–2000) | 2000 (2000–2000) | 0.136 |
| C/D ratio – tacrolimus concentration to drug ratio; CPRA – calculated panel reactive antibody; IR-Tac – immediate release tacrolimus; MMF – mycophenolate mofetil; Q1 – first quartile; Q3 – third quartile; SD – standard deviation. | ||||